12:00 AM
Aug 29, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Faslodex fulvestrant regulatory update

The U.K.'s NICE issued a preliminary appraisal recommending against Faslodex fulvestrant from AstraZeneca as an alternative to aromatase inhibitors to treat hormone-receptor-positive, locally advanced or metastatic breast cancer in postmenopausal women whose cancer has relapsed or progressed. NICE said the company's estimates of...

Read the full 201 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >